Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to heal hearts after attack – trial results awaited

NCT ID NCT05350969

Disease control Sponsor: Cardior Pharmaceuticals GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 2 times

Summary

This study tested a new medicine called CDR132L in 294 people who had a recent heart attack and had weak heart pumping (ejection fraction 45% or less). Participants received one of two doses of CDR132L or a placebo, added to standard care, for 6 months. The goal was to see if the drug safely improves heart function and reduces heart failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

294 people

The number who actually took part.

Started

Jul 2022

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria: 1. Male or female patients, aged ≥ 30 to ≤ 80 years at the date of signing informed consent which is defined as the beginning of the Screening Period. 2. Spontaneous acute mycardial infarction (AMI) (type I) based on the universal MI definition with randomization to occur no later than 14 days after index event diagnosis. 3. Patient with a LVEF ≤ 45% as measured by ECHO after MI diagnosis (STEMI or NSTEMI). 4. Patient with previous MI events in history can be included. 5. Patient with body weight of ≤ 120 kg. 6. N-terminal pro B-type natriuretic peptide level ≥ 125 pg/ml and \< 8000 pg/ml at screening. 7. Patient with STEMI/NSTEMI who underwent percutaneous coronary intervention for this event. Exclusion Criteria: 1. A woman of childbearing potential (WOCBP). 2. Patient with HF of non-ischemic origin; e.g., myocarditis, alcoholic cardiomyopathy. 3. Patient with New York Heart Association (NYHA) class IV at screening or randomization. 4. Patient has any planned cardiac intervention (angiogram without angioplasty is acceptable) or any other planned surgery after the Screening Period. 5. Patient has severe valvular heart disease. 6. Patient has systolic BP \< 90 mmHg or \> 180 mmHg, diastolic BP \< 50 mmHg or \> 110 mmHg, and/or heart rate \< 50 or \> 100 beats/minute at screening or randomization. 7. Patient with an estimated glomerular filtration rate \< 30 mL/min/1.73 m2 or on dialysis. 8. Patient with hepatic insufficiency classified as Child-Pugh B or C. 9. Patient has medical history of disease(s) affecting the blood-brain-barrier, e.g., stroke within 6 months or multiple sclerosis. 10. Patient has medical history of bleeding disorders or has thrombocytopenia (platelets \< 100,000/μL). 11. Patient has poorly controlled diabetes as determined by the Investigator. 12. Patient has a history or presence of any of the following cardiac conditions: known structural cardiac abnormalities beyond HF, family history of long QT syndrome, cardiac syncope, or recurrent, idiopathic syncope. 13. Any clinically significant abnormalities, at the discretion of the Investigator, in rhythm, conduction, or morphology of resting ECG that pose an additional safety risk to patients. 14. Patient with active "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" infection confirmed as per the local testing guidelines at screening. 15. Patient is not to be enrolled into the study if they received any prohibited therapy within 3 months of screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure with reduced ejection fraction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction heart failure left ventricular failure myocardial infarction systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure, left-sided Myocardial infarction, acute

Contacts and locations

Locations

  • "Alexandra" General Hospital of Athens

    Athens, Greece

  • "Attikon" General University Hospital

    Athens, Greece

  • Complejo Hospitalario Universitario de Vigo

    Vigo, Spain

  • D & A Research B.V.

    Sneek, Netherlands

  • Deventer Ziekenhuis

    Deventer, Netherlands

  • Erasmus University Medical Center

    Rotterdam, Netherlands

  • Gabinet Internistyczno-Kardiologiczny Jacek Nowak

    Libiąż, Poland

  • Gelderse Vallei Ziekenhuis

    Ede, Netherlands

  • Gelre Ziekenhuizen

    Zutphen, Netherlands

  • General University Hospital of Patras "Panagia i Voitheia"

    Pátrai, Greece

  • Helios Klinikum Erfurt

    Erfurt, Germany

  • Herzzentrum Dresden Universitätsklinik

    Dresden, Germany

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain

  • Hospital Universitari Germans Trias i Pujol

    Badalona, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario San Cecilio

    Granada, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Spain

  • Hospital Universitario Virgen de la Arrixaca

    Murcia, Spain

  • Hospital Universitario de Sabadell

    Sabadell, Spain

  • Hospital de la Santa Creu I Sant Pau

    Barcelona, Spain

  • Ikazia Ziekenhuis

    Rotterdam, Netherlands

  • Institut klinicke a experimentalni mediciny

    Prague, Czechia

  • Investigational Site

    Wroclaw, Poland

  • Jeroen Bosch Ziekenhuis (JBZ) (Hieronymus Bosch Hospital) - locatie Den Bosch

    's-Hertogenbosch, Netherlands

  • Klinikum Ludwigshafen

    Ludwigshafen, Germany

  • Krakowski Szpital Specjalistyczny im. Jana Pawla II

    Krakow, Poland

  • Medicome Sp. z o.o.

    Oświęcim, Poland

  • Medisch Centrum Leeuwarden

    Leeuwarden, Netherlands

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog

    Sopot, Poland

  • NZOZ SALUS JZ Peruga

    Lodz, Poland

  • One wojskowy Szpital Kliniczny w Lublinie

    Lublin, Poland

  • Polsko Amerykanskie Kliniki Serca

    Kędzierzyn-Koźle, Poland

  • Queen Elizabeth University Hospital

    Glasgow, United Kingdom

  • Richmond Pharmacology Limited

    London, United Kingdom

  • Semmelweis University

    Budapest, Hungary

  • Slingeland Ziekenhuis

    Doetinchem, Netherlands

  • South Tees Hospital NHS Foundation Trust

    Middlesbrough, United Kingdom

  • Spec.Szpital im.dr Sokolowskiego

    Wałbrzych, Poland

  • Specjalistyczna Poradnia Kardiologiczna i Nadcisnienia Tetniczego

    Kielce, Poland

  • St. Jansdal Ziekenhuis

    Lelystad, Netherlands

  • St. Marien-Krankenhaus Ahaus

    Ahaus, Germany

  • Universitätsklinikum Schleswig-Holstein

    Kiel, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Germany

  • Universitätsmedizin Göttingen

    Göttingen, Germany

  • Všeobecná fakultní nemocnice v Praze

    Prague, Czechia

  • Wojewodzki Szpital Zespolony

    Torun, Poland

  • Wojewódzki Szpital im. Sw. Ojca Pio w Przemyslu

    Przemyśl, Poland

  • Wycombe Hospital

    High Wycombe, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.